PosiRx automated radiopharmaceutical system
introducing PosiRx : Positron Corporation would like to introduce PosiRx, the future of radiopharmaceutical dose preparation and delivery. PosiRx is a radiopharmaceutical system that automates the elution, preparation and dispensing processes for radiopharmaceutical agents used in molecular imaging. It was created to simplify and control the procedures associated with compounding radiopharmaceuticals. PosiRx integrates features that increase productivity while decreasing exposure and costs. Our system provides molecular imaging departments with 24/7 unit dose accessibility, combined with the reliability of an on-site supply. Additionally, PosiRx assists in compliance with all current USP-797 requirements for the production of unit dose radiopharmaceuticals.
the evolution of radiopharmaceutical preparation and delivery Today s molecular imaging community faces challenges with radiopharmaceutical preparation; challenges that include uncertainties with dose delivery and accuracy, inefficient manual preparation, and maintaining compliance with USP requirements. Many aspects of pharmacy, drug, and chemical preparation have been automated in other areas of the industry; however, PosiRx is the first system of its kind to offer a complete and comprehensive automated solution in Nuclear Medicine.
simplify The PosiRx system has simplified the steps involved in dose preparation and delivery by automating many of the compounding processes including generator elution, kit compounding, unit dose preparation and generator QC. This automation allows PosiRx to minimize the possibility of an operator introducing contaminants into the compliant environment and ensures consistency in each step of the dose delivery process. PosiRx is a self-contained system that provides immediate availability of a radiopharmaceutical supply around the clock. This automation and availability increases productivity and reduces operational costs. The PosiRx system allows the operator to manage every aspect of the compounding and dose drawing process with high levels of accuracy and reproducibility. Procedures are executed through an intuitive user interface with a few touchscreen inputs. The simplicity of its operation reduces the need for extensive training, resulting in improved output and a reallocation of resources. control PosiRx addresses the ever-changing financial environment of the molecular imaging community by granting its users full control and freedom over their facility s radiopharmaceutical supplies and schedules. Doses can be customized and drawn as needed, reducing operational cost and improving patient management. The convenience of an on-site unit dose radiopharmaceutical supply also allows PosiRx users the ability to expand their compounding capacity. The PosiRx system provides total security as all radioactive materials are locked in a protective enclosure. Varying security levels, which authorize control and permit operation of the system can be assigned to personnel. Lot and operator information can also be provided and printed out, allowing management access to data regarding specific operators and procedures. PosiRx also creates an ISO Class 5 environment that is essential for allowing users to prepare and handle radiopharmaceuticals. During the development of this system, engineers implemented the principles of ALARA into its design by strategically shielding the user and reducing the time spent in proximity to the radioactive source. By combining automation and shielding, technologists are exposed to little or no radiation during the compounding process. Additionally, PosiRx reduces the number and complexity of protocols necessary for compliance with current USP-797 requirements.
key features // Automated dose drawing and compounding // Automated generator elution // Simplification of USP-797 compliance // ISO Class 5 environment // Exposure control // Operational efficiency and cost control // On-site convenience configurations The PosiRx system is configured to compound and dispense several currently utilized radiopharmaceuticals. Configurations optimized for compounding Sestamibi, Tetrofosmin and several other SPECT radiopharmaceuticals are available.
55 35 80 design footprint height... 80 width... 55 depth... 35 weight... <2,000 lbs power requirement... 110V/15A contact 7715 loma court, suite a fishers, indiana 46038 p 866.613.7587 f 317.576.0358 sales@positron.com www.positron.com 156-00005 Rev 00 DESIGNED BY AUDACITY // AUDACITYGROUP.COM